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background:  ETC-1002 is an oral investigational drug that modulates adenosine triphosphate-citrate lyase and adenosine 
monophosphate-activated protein kinase and may be beneficial in treating hypercholesterolemia, particularly in patients with statin 
intolerance.
Methods:  A double-blind, parallel group, multicenter trial evaluated 348 patients with (n=177) or without (n=171) muscle-related statin 
intolerance (to ≥2 statins, 1 at lowest dose) and LDL-C of 130-220 mg/dL randomized to ETC-1002 120 mg, ETC-1002 180 mg, ezetimibe 
10 mg (eze), ETC-1002 120 mg + eze, or ETC-1002 180 mg + eze once daily for 12 weeks.
Results:  At baseline, LDL-C was 165±25 mg/dL (mean±SD). ETC-1002 120 mg (p=0.0008) and 180 mg (p<0.0001) lowered LDL-C more 
than eze (primary endpoint); as did ETC-1002 + eze groups (p<0.0001). ETC-1002 also lowered C-reactive protein (CRP), apolipoprotein 
B, non-high density lipoprotein-cholesterol (nonHDL-C) and LDL particle # more than eze. ETC-1002 was well-tolerated; muscle-related 
adverse events were similar across 120 mg, 180 mg, eze, 120 mg + eze, and 180 mg + eze treatments and higher in the subgroup with 
(14%, 12%, 18%, 17%, 17%) versus without (2%, 0%, 6%, 0%, 8%) statin intolerance.
conclusion:  In patients with hypercholesterolemia, including those with statin intolerance, ETC-1002 is a potential new therapy with 
greater LDL-C lowering than eze and with a similar safety and tolerability profile. The utility of ETC-1002 + eze therapy merits further 
investigation.
Percent Change from Baseline Following 12 Week Treatment
Treatment n LDL-CLS Mean (SE)
nonHDL-C
LS Mean (SE)
CRP
Median (IQR)
ETC-1002 120 mg 99 -27% (1.3)* -23% (1.2)* -30% (55)*
ETC-1002 180 mg 100 -30% (1.3)* -25% (1.1)* -40% (53)*
Ezetimibe 99 -21% (1.3) -19% (1.2) -10% (59)
ETC-1002 120 mg + Ezetimibe 26 -43% (2.6)* -37% (2.3)* -38% (83)
ETC-1002 180 mg + Ezetimibe 24 -48% (2.8)* -42% (2.4)* -26% (37)*
*p<0.05 vs ezetimibe; LS, least squares; SE, standard error; IQR, interquartile range.
